Transitioning from Trelegy and DuoNeb to Yupelri

Introduction to COPD Management

The American Thoracic Society explicitly recommends avoiding concurrent use of Trelegy and Yupelri because both contain long-acting muscarinic antagonists, which increases the risk of adverse effects without additional clinical benefit 1
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines state that triple therapy should be delivered as a single regimen, not duplicated across multiple devices, and adding a second LAMA to existing triple therapy has no supporting evidence 1

The American College of Chest Physicians recommends discontinuing Yupelri immediately, as the umeclidinium component in Trelegy provides adequate LAMA coverage 1
The American College of Chest Physicians also recommends continuing Trelegy as the sole maintenance therapy, which provides complete triple therapy in a single once-daily inhaler 1
Reassess symptom control after 2-4 weeks on optimized therapy, and consider alternative triple therapy regimens or step-down to dual therapy if necessary 1, 2

The European Respiratory Society notes that Trelegy's once-daily Ellipta device offers superior convenience compared to nebulized Yupelri, which requires daily nebulizer setup and cleaning 1
Dry powder inhalers like Ellipta have lower error rates (10-40%) compared to metered-dose inhalers (76% error rate) 1, 4
Inhaler technique must be demonstrated at prescription and checked at every follow-up visit to improve adherence and reduce errors 1, 4

The American College of Chest Physicians reports that Trelegy contains fluticasone furoate (ICS), which carries a 4% increased risk of pneumonia compared to bronchodilators alone 1
Monitor for signs of pneumonia: new or worsening dyspnea, fever, increased sputum production or purulence 1
The American Thoracic Society recommends reviewing concurrent anticholinergic medications to avoid additive anticholinergic burden 1
The British Thoracic Society recommends avoiding beta-blocking agents (including ophthalmic preparations) in all COPD patients on bronchodilator therapy, as they can antagonize the vilanterol component in Trelegy 1